Likewise, other potential biomarkers, such as the tumor mutation burden, microsatellite instability, and CD8+ T lymphocytes, have been evaluated, and some of them are linked to approved indications [10, 11], but no powerful predictors of PD-1 blockade efficacy have been discovered [12]. The gene discussed is CD8A; the disease is neoplasm.